SOPH
SOPHiA GENETICS S.A.
$4.88
-0.17
(-3.37%)
Mkt Cap
349.74M
Volume
99,981
52W Range
2.59-5.7
Sector
Healthcare
Beta
1.01
EPS (TTM)
-1.18
P/E Ratio
-3.99
Revenue (TTM)
81.18M
Rev Growth (5Y)
+22.2%
EPS Growth (5Y)
N/A
Company Description
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 77.27M | 65.17M | 62.37M | 47.56M | 40.45M | 28.40M | 25.36M |
| Net Income | (79.00M) | (62.49M) | (78.98M) | (87.45M) | (73.67M) | (39.34M) | (33.79M) |
| EPS | -1.17 | -0.95 | -1.22 | -1.36 | -1.33 | -0.82 | -0.53 |
| Free Cash Flow | (38.59M) | (51.00M) | (57.80M) | (80.47M) | (64.61M) | (34.93M) | (34.71M) |
| FCF / Share | -0.57 | -0.78 | -0.89 | -1.26 | -1.17 | -0.73 | -0.54 |
| Operating CF | (38.01M) | (42.82M) | (48.58M) | (70.09M) | (57.94M) | (31.73M) | (31.68M) |
| Total Assets | 163.46M | 155.31M | 206.16M | 243.84M | 320.17M | 132.12M | 51.66M |
| Total Debt | 63.02M | 30.03M | 18.60M | 16.74M | 13.06M | 7.25M | 8.46M |
| Cash & Equiv | 70.29M | 80.23M | 123.25M | 161.31M | 192.96M | 74.62M | 18.07M |
| Book Value | 47.15M | 96.49M | 151.44M | 200.13M | 275.40M | 100.51M | 22.25M |
| Return on Equity | -1.68 | -0.65 | -0.52 | -0.44 | -0.27 | -0.39 | -1.52 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.69M | 21.71M | 19.46M | 18.32M | 17.78M | 17.73M | 15.85M | 15.81M | 15.78M | 17.05M | 16.30M | 15.05M |
| Net Income | (19.32M) | (19.18M) | (20.02M) | (22.41M) | (17.39M) | (15.16M) | (18.44M) | (15.19M) | (13.70M) | (24.06M) | (13.82M) | (21.40M) |
| EPS | -0.27 | -0.28 | -0.30 | -0.33 | -0.26 | -0.23 | -0.28 | -0.23 | -0.21 | -0.37 | -0.21 | -0.33 |
| Free Cash Flow | (17.06M) | (9.28M) | (8.90M) | (10.19M) | (12.24M) | (12.54M) | (9.48M) | (12.37M) | (16.60M) | (13.54M) | (14.27M) | (13.47M) |
| FCF / Share | -0.24 | -0.14 | -0.13 | -0.15 | -0.18 | -0.19 | -0.14 | -0.19 | -0.25 | -0.21 | -0.22 | -0.21 |
| Operating CF | (16.18M) | (8.94M) | (8.79M) | (8.21M) | (10.75M) | (10.60M) | (7.16M) | (10.42M) | (14.64M) | (11.29M) | (12.17M) | (10.32M) |
| Total Assets | 157.00M | 163.46M | 163.46M | 177.62M | 146.72M | 155.31M | 177.61M | 181.10M | 180.26M | 206.16M | 205.85M | 223.20M |
| Total Debt | 62.42M | 63.02M | 63.37M | 63.81M | 30.13M | 30.03M | 31.67M | 30.07M | 17.44M | 18.60M | 17.87M | 19.82M |
| Cash & Equiv | 65.39M | 70.29M | 81.61M | 94.82M | 68.53M | 80.23M | 95.79M | 105.40M | 103.73M | 123.25M | 132.77M | 148.55M |
| Book Value | 45.69M | 47.15M | 60.69M | 76.69M | 85.61M | 96.49M | 113.51M | 121.44M | 132.23M | 151.44M | 158.44M | 171.70M |
| Return on Equity | -0.42 | -0.41 | -0.33 | -0.29 | -0.20 | -0.16 | -0.16 | -0.13 | -0.10 | -0.16 | -0.09 | -0.12 |
SOPH News
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
SOPHiA GENETICS Reports First Quarter 2026 Results
SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
SOPHiA GENETICS (NASDAQ:SOPH) & Hims & Hers Health (NYSE:HIMS) Financial Comparison
SOPHiA GENETICS Q4 Earnings Call Highlights
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results